Form 4 for SYRE Spyre Therapeutics, Inc.
Accepted 2022-06-10 00:00:00 ET · period of report 2022-06-08 · accession 0001209191-22-036085 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022-06-10 | 2022-06-08 | SYRE | Hanley Jr. Michael Conick | Chief Commercial Off | P - Purchase | $0.71 | +28.2K | 36.2K | +352% | +$20.0K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-06-08 | P | A | 28,200 | $0.71 | 36,200 | D | — | — | (F1) Includes 8,000 shares of common stock acquired by the Reporting Person pursuant to the Issuer's employee stock purchase plan. |